NEW YORK, January 4, 2017 /PRNewswire/ --
Stock-Callers.com shifts its attention to four Medical Instruments and Supplies equities, which are OraSure Technologies Inc. (NASDAQ: OSUR), Integra LifeSciences Holdings Corp. (NASDAQ: IART), Tandem Diabetes Care Inc. (NASDAQ: TNDM), and West Pharmaceutical Services Inc. (NYSE: WST). These companies belong to the Healthcare sector, which lead the US markets higher on Tuesday, January 03rd, 2017, with the NYSE Health Care Index rising almost 0.7%, and shares of health care companies in the S&P 500 climbing more than 1.1% as a group. These stocks research reports can be downloaded now by simply registering for free at:
Bethlehem, Pennsylvania-based OraSure Technologies Inc.'s stock finished Tuesday's session 0.11% higher at $8.79 with a total trading volume of 348,899 shares. The Company's shares have advanced 2.81% in the past month, 9.46% over the previous three months, and 0.11% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.24% and 16.12%, respectively. Furthermore, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 54.33.
On November 29th, 2016, OraSure Technologies announced that it will begin fulfilling a contract to supply a foreign government with $18 million of product, primarily to support a nationwide hepatitis C (HCV) testing and treatment program with the goal of eliminating HCV infection across the country by 2020. The contract calls for the purchase of $16 million of OraQuick® HCV Rapid Antibody Tests and $2 million of OraQuick® Rapid HIV-1/2 Antibody Tests. Your complete research report on OSUR can be retrieved for free at:
Shares in Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp. ended at $85.18, declining 0.71% from the last trading session. The stock recorded a trading volume of 356,635 shares. The Company's shares have gained 10.84% in the last one month and 2.47% over the previous three months. The stock is trading 5.03% above its 50-day moving average and 8.65% above its 200-day moving average. Moreover, shares of Integra LifeSciences Holdings, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, have an RSI of 63.72.
On December 12th, 2016, research firm UBS initiated a 'Buy' rating on the Company's stock, with a target price of $96 per share.
On December 22nd, 2016, Integra LifeSciences announced that its stockholders approved a two-for-one stock split and an increase from 60 million to 240 million authorized shares of its common stock at a special meeting of stockholders held on December 21st, 2016. Holders of record, as of the close of markets on December 21st, 2016, will be entitled to receive one additional share of common stock for each share held. The adjusted stock price is expected to be reflected on the NASDAQ stock market on January 04th, 2017. IART free report is just a click away at:
Tandem Diabetes Care
San Diego, California headquartered Tandem Diabetes Care Inc.'s stock ended yesterday's session 2.33% lower at $2.10 with a total trading volume of 269,490 shares. The Company's shares are trading 28.78% below their 50-day moving average. Shares of the Company, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have an RSI of 43.71.
On November 29th, 2016, Tandem Diabetes announced that it has initiated the drawdown of $35 million under the company's previously announced term loan facility with Capital Royalty Partners II L.P. and its affiliated funds. Sign up for your complimentary research report on TNDM at:
At the close on Tuesday, shares in Exton, Pennsylvania headquartered West Pharmaceutical Services Inc. recorded a trading volume of 566,315 shares, which was higher than their three months average volume of 364,520 shares. The stock finished 0.90% lower at $84.07. The Company's shares have advanced 5.46% in the last one month and 13.08% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 5.24% and 10.17%, respectively. Furthermore, shares of West Pharmaceutical Services, which develops, manufactures, and sells packaging and delivery systems in the US, Germany, France, Other European countries, and internationally, have an RSI of 58.92.
On December 14th, 2016, West Pharmaceutical's Board of Directors declared a Q1 2017 dividend of $0.13 per share. The dividend will be paid on February 01st, 2017, to shareholders of record as of January 18th, 2017. The Company also announced a share repurchase program authorizing the repurchase of up to 800,000 shares of its common stock from time to time on the open market or in privately-negotiated transactions. Register for free on Stock-Callers.com and download the latest research report on WST at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA